Feedback / Questions
nilotinib amorphous (XS003) - Xspray Pharma
https://www.businesswire.com/news/home/20250819098597/en/Xspray-Pharma-Submits-XS003-to-the-FDA-The-Companys-Second-Product-Candidate-from-the-HyNap-Platform
Aug 19, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next